Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

Enzene’s CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier’s India visit, he also talks about front-loading capacity at Enzene’s US plant and a change in its biosimilars strategy

Source : https://insights.citeline.com/

Date: 22/04/2025

Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

The future begins now

Your biologic deserves the most technologically advanced manufacturing process in the industry. And you deserve a new way to think about strategic partnership. Today is just the beginning.